3 insiders bought €553k of shares over the last 90 days, the latest filed 25 Aug 2026.
A2M is a listed company. Filings by its managers are published through ASX. Between 18 October 2025 and 18 October 2026, 6 insiders published 8 filings.
The flow runs one way only: 3 insiders bought (3 purchases totalling €553k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The largest single trade was a purchase of €357k by Grant Andrew Dempsey, published on 25 August 2026, equal to 0.012% of the market capitalisation. The buyers include 3 senior executives.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 25 August 2026, 53 days ago. Filings reach the ASX feed a median of 6 days after the trade. That lag is the time during which only the insider knows about the trade.
With 8 filings in twelve months, the company is more active than the median of 3 filings across the 2,527 companies we follow on the same exchange. The full history, which starts in 2026, counts 3 purchases against no sales.
Every figure here comes from the filings published by ASX and describes the past, not future prices; it is not investment advice.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate A2M Buy (bullish), based on 10 analysts. Average price target: A$7.53.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended June 2026 · cache
8 of 8 declarations
A2M is a company listed on the XASX, specializing in the development of health products. It focuses on innovation in the healthcare sector.